Respiratory syncytial virus prophylaxis with nirsevimab: impact beyond hospitalisations

Cristina Calvo^{1

2

3}, María Luz García-García^{4

2}

Affiliations

¹ Paediatric Infectious and Tropical Diseases Department, La Paz University Hospital, Institute for Health Research IdiPAZ, Madrid, Spain.
² CIBERINFEC, Carlos III Health Institute, Madrid, Spain.
³ Paediatric Department, Autonomous University of Madrid, Madrid, Spain.
⁴ Paediatric Department, Severo Ochoa University Hospital, Leganés, Madrid, Spain.

Cristina Calvo et al. Lancet Reg Health Eur. 2025.

. 2025 Jun 11:55:101349.

doi: 10.1016/j.lanepe.2025.101349. eCollection 2025 Aug.

Cristina Calvo^{1

2

3}, María Luz García-García^{4

2}

¹ Paediatric Infectious and Tropical Diseases Department, La Paz University Hospital, Institute for Health Research IdiPAZ, Madrid, Spain.
² CIBERINFEC, Carlos III Health Institute, Madrid, Spain.
³ Paediatric Department, Autonomous University of Madrid, Madrid, Spain.
⁴ Paediatric Department, Severo Ochoa University Hospital, Leganés, Madrid, Spain.

No abstract available

Conflict of interest statement

The authors declare no conflicts of interest.

1. Perramon-Malavez A., Buonsenso D., Morello R., et al. Real-world impact of nirsevimab immunisation against respiratory disease in infants: a multi-national retrospective analysis of emergency department attendances and admissions. Lancet Reg Health Eur. 2025 doi: 10.1016/j.lanepe.2025.101334. - DOI
1. Grupo de Trabajo utilización de nirsevimab frente a infección por virus respiratorio sincitial de la Ponencia de Programa y Registro de Vacunaciones. Comisión de Salud Pública del Consejo Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad; 2023. https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/comoTr...
1. Griffin M.P., Yuan Y., Takas T., et al. Nirsevimab Study Group Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383(5):415–425. doi: 10.1056/NEJMoa1913556. - DOI - PubMed
1. Sumsuzzman D.M., Wang Z., Langley J.M., Moghadas S.M. Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysis. Lancet Child Adolesc Health. 2025;9(6):393–403. doi: 10.1016/S2352-4642(25)00093-8. - DOI - PubMed
1. Andina Martínez D., Claret Teruel G., Gijón Mediavilla M., et al. Impact of universal respiratory syncytial virus prophylaxis in Spain Working Group. Nirsevimab and acute bronchiolitis episodes in pediatric emergency departments. Pediatrics. 2024;154(4) doi: 10.1542/peds.2024-066584. - DOI - PubMed